American Psychiatric Association

American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

Retrieved on: 
Thursday, July 6, 2023
American Medical Association, American Psychiatric Association, Medical Affairs Bureau, Senior, CPT, PBC, Continuity, American Psychological Association, National Association of Social Workers, COMPASS, Language, EDT, Ensuring Patient Access and Effective Drug Enforcement Act, Social work, MAPS, Post-traumatic stress disorder, Current Procedural Terminology, Webcast, CMPS, National Association, FDA, Mental health, III, Flour, Pharmaceutical industry, Nursing

The code will go into effect and will be published in the CPT manual on January 1, 2024.

Key Points: 
  • The code will go into effect and will be published in the CPT manual on January 1, 2024.
  • The approval of the new category CPT III code, announced in May following an application by COMPASS and MAPS Public Benefit Corporation (MAPS PBC), was supported by the American Psychiatric Association, American Psychological Association and the National Association of Social Workers.
  • The use of this category III tracking code will be key to developing optimal permanent and valued category I codes for psychedelic therapies as close as possible to their potential FDA approval.
  • The webinar will feature:
    Dr. Steve Levine, Senior Vice President of Patient Access and Medical Affairs at COMPASS.

The Inner Circle Acknowledges, Irene Mazur as a Top Pinnacle Professional for her contributions to the field of Psychiatry

Retrieved on: 
Thursday, June 22, 2023
Cognition, Psychiatry, American Psychiatric Association, Emotional and behavioral disorders, Depression, Education, Anxiety, UMDNJ, ADHD, Woman, Research, DSM-IV codes, Women in medicine, Geriatrics, Inner circle, Nursing, MD, Patient, Child, Brown University, Adolescence, Diagnosis, Mental health, Behavior, Medicine

MILESTONE, N.J., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Irene Mazur is acknowledged as a Top Pinnacle Professional for her contributions to the field of Psychiatry.

Key Points: 
  • MILESTONE, N.J., June 22, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Irene Mazur is acknowledged as a Top Pinnacle Professional for her contributions to the field of Psychiatry.
  • Dr. Mazur pursued higher education from Terlopil University in the Ukraine 1992 where she earned a medical degree with honors.
  • Highly renowned in her field, Dr. Mazur practices telepsychiatry treating children, adolescents, and adults for ADHD, depression, and anxiety at the Center of Revitalizing Psychiatry.
  • She has been married to Yuri Mazur, MD for 26 years and they have 3 sons.

Is it anxiety or ADHD, or both? How to tell the difference and why it matters

Retrieved on: 
Tuesday, June 20, 2023
American Psychiatric Association, Learning, Depression, Anxiety, Failure, Life, Attention deficit hyperactivity disorder predominantly inattentive, Parent, American, ADHD, Eating, Woman, Attention, Mindfulness, Man, Social media, Hearing, Motivation, Generalized anxiety disorder, Diagnosis, Mental health, Family, Irritability, Fatigue, Nursing, Dietary supplement, Property insurance, Vaccine, Toy, Medical device

She has taken anxiety medication but it didn’t help much.

Key Points: 
  • She has taken anxiety medication but it didn’t help much.
  • Social media abounds with stories of people who have, without success, taken medication for anxiety and are now wondering about possible undiagnosed ADHD.
  • So, how can you tell if it’s anxiety or ADHD, or both?

ADHD and anxiety can go hand-in-hand

    • On the other hand, a pattern of being late, missing deadlines and forgetting appointments due to ADHD may lead to anxiety and a sense of failure.
    • Anxiety and depression are both commonly associated with ADHD, particularly in women.
    • Anxiety tends to be more severe and persistent and with a younger age of onset in people with ADHD.
    • Successful treatment of co-existing ADHD may, for some, be the best way of getting relief from chronic anxiety.

Could ADHD be a factor?

    • ADHD is often subtle in girls and women, who are less likely to show the disruptive hyperactive behaviour that draws attention to ADHD in men and boys.
    • This matters because women with ADHD have higher rates of depression, anxiety, eating and sleep disorders.
    • However, not all adults with ADHD showed signs of it in childhood.

ADHD in adulthood

    • Problematically, these criteria require that to be diagnosed with ADHD, an adult should have experienced difficulties before the age of 12.
    • Studies have identified ADHD in adults who didn’t show evidence of it when previously assessed in childhood.
    • And ADHD is generally assessed in adults as if it were a continuation of the childhood condition.

If I suspect ADHD, what now?

    • If you suspect ADHD but are able to get on fine in life, you probably don’t need a diagnosis.
    • This could mean disorganisation, inefficiency, difficulty with relationships at work or in the family, or depression or anxiety so severe it affects your ability to function.
    • However, many people who outwardly appear to be coping well may find it difficult to convince a GP an assessment is necessary.
    • An ADHD diagnosis can be a relief for some, who may find treatment helps alleviate problems they’d previously blamed on anxiety.

New APA Poll Finds Americans Rate Cigarettes as Most Unsafe, Addictive Substance Among Options Surveyed

Retrieved on: 
Thursday, June 8, 2023
Intussusception (medical disorder), APA, Tobacco, Medicine, Addiction, Diagnosis, American Psychiatric Association, Opioid, Research, Naloxone, Safety, Herbal cigarette, Pharmaceutical industry

“It is clear that we have gotten the message through that cigarettes are dangerous and addictive,” said APA President Petros Levounis, M.D., M.A.

Key Points: 
  • “It is clear that we have gotten the message through that cigarettes are dangerous and addictive,” said APA President Petros Levounis, M.D., M.A.
  • “We can help prevent more Americans from other potentially addictive behaviors, like drinking alcohol and technology use.
  • For instance, vaping is just as, if not more addictive than cigarette smoking.
  • We can also make sure that people know about our current safe and effective treatments for both substance use disorders and the behavioral addictions.

TrueCoach and Restoic Join Forces to Enhance Athletes' Confidence, Reduce Anxiety, and Optimize Performance

Retrieved on: 
Wednesday, June 7, 2023
Well, American Psychiatric Association, MLS, WNBA, Partnership, Overalls, Athlete, NWSL, MLB, Physical fitness, Health, Fitness, Mental health, Tutoring, Nursing

ATLANTA, June 7, 2023 /PRNewswire/ -- TrueCoach, the premier online platform for personal trainers under Xplor Technologies, has today announced a partnership with Restoic, a state-of-the-art wellness platform for athletes at all levels seeking to train their minds and optimize performance through mental skills training. The partnership between TrueCoach and Restoic brings an array of benefits to coaches by enhancing their ability to support clients' mental health and overall well-being alongside their physical fitness.

Key Points: 
  • TrueCoach personal trainers can now include Restoic breathwork and visualization videos into workout programming to help their clients relax and recover.
  • The partnership between TrueCoach and Restoic brings an array of benefits to coaches by enhancing their ability to support clients' mental health and overall well-being alongside their physical fitness.
  • From Olympic gold medalists to MLB players, MLS, NWSL, and WNBA athletes, Restoic is the go-to mental training platform.
  • With TrueCoach Partner Perks, coaches and clients are eligible for exclusive preferential pricing on Restoic purchases, unlocking a wealth of resources beyond the 1200+ training videos available in the TrueCoach library.

IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Managed Care, Other Health, Health, Pharmaceutical, Mental Health, Other Science, Research, Genetics, Science, Clinical Trials, American Psychiatric Association, Depression, Anxiety, APA, RCT, DNP, NP-C, Patient, Annual general meeting, Pharmaceutical industry

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced real-world study data demonstrating that use of IDgenetix® to guide medication management can significantly improve medication response and remission rates in patients diagnosed with moderate to severe depression, compared to current standard-of-care treatment.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced real-world study data demonstrating that use of IDgenetix® to guide medication management can significantly improve medication response and remission rates in patients diagnosed with moderate to severe depression, compared to current standard-of-care treatment.
  • The data was shared via a poster presentation at the May 2023 American Psychiatric Association (APA) Annual Meeting held in San Francisco.
  • “As supported by the data in this study, using IDgenetix to guide personalized medication selection can help improve the care of patients suffering from moderate to severe depression by offering hope of improved medication response and remission.”
    In the study, patients whose medication management was guided by IDgenetix achieved a 35% increase in medication response and a 64% increase in remission rate at eight weeks compared to patients whose medication was not guided by the test.
  • In an RCT, patients diagnosed with severe depression whose medication management was guided by the IDgenetix test showed a greater than two and a half times improvement in remission rates at eight and 12 weeks compared to those who were not guided by IDgenetix.1

HMP Global's East Coast Symposium announces American Psychiatric Association President Petros Levounis joins speaker lineup as keynote

Retrieved on: 
Wednesday, May 24, 2023
Harm reduction, American Psychiatric Association, Senior, Education, Addiction, APA, Quality of life, Neuroscience, Brain, Mental health, Teaching hospital, Bristol Community College, Social, Patient, Drug, Pain management, Psychiatry, New Jersey Medical School, Cannabis, Ethics, MPA, Health, Function (mathematics), Trauma, Family, Counselor, Pharmaceutical industry, Nursing, MD

MALVERN, Pa., May 24, 2023 /PRNewswire-PRWeb/ -- In the ever-changing field of addiction treatment, HMP Global's 2023 East Coast Symposium will provide the latest strategies and emerging trends, including a keynote presentation on the neurobiological attributes of addiction, presented by Petros Levounis, MD, MA, the new President of the American Psychiatric Association (APA).

Key Points: 
  • MALVERN, Pa., May 24, 2023 /PRNewswire-PRWeb/ -- In the ever-changing field of addiction treatment, HMP Global's 2023 East Coast Symposium will provide the latest strategies and emerging trends, including a keynote presentation on the neurobiological attributes of addiction, presented by Petros Levounis, MD, MA, the new President of the American Psychiatric Association (APA).
  • Dr. Levounis' keynote, "Neurobiology of Addiction in 2023," will be held from 8:30 – 9:30 a.m. Friday, November 3.
  • The East Coast Symposium features more than 35 national expert speakers presenting a robust, three-day educational program, and opportunities to earn more than 16 CME/CE credits.
  • Previously known as NCAD East, the East Coast Symposium is one of four premier educational events focused on providing timely education for addiction treatment and behavioral health professionals.

Teva to Present Data Demonstrating UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolonged Time to Impending Relapse for Adults with Schizophrenia at the American Psychiatric Association’s 2023 Annual Meeting

Retrieved on: 
Saturday, May 20, 2023
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Teva Pharmaceuticals, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Abstract (summary), Abstract, Donald, TEVA, Yahoo Beijing Global R&D Center, University, Teva, TD, De novo, Social, APA, Absorption, Patient, Doctor of Philosophy, University of Michigan School of Social Work, Medication, Risperidone, Neuroscience, American Psychiatric Association, Professor, DE, MD, Physician, Region, TASE, Annual general meeting, RISE, Diagnosis, Caregiver, FDA, Maintenance, Tardive dyskinesia, NYSE, SHINE, Pharmaceutical industry, Nursing, Schizophrenia

Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the treatment of schizophrenia in adults.

Key Points: 
  • Abstracts include data for UZEDY (risperidone) extended-release injectable suspension for subcutaneous use, which was recently approved by the FDA for the treatment of schizophrenia in adults.
  • Additional abstracts being presented include data on characteristics that impact TD diagnosis and machine-learning to identify unique patient segments for TD.
  • UZEDY utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell, that controls the rate and duration of risperidone release.
  • This year’s annual APA meeting is being offered both in person and virtually.

Erase PTSD Now Kicks Off Campaign to Change the Term PTSD (Post Traumatic Stress Disorder) to PTSI (Post-Traumatic Stress Injury)

Retrieved on: 
Monday, May 15, 2023
Survivor, American Psychiatric Association, Plague, Sympathetic nervous system, APA, Diagnosis, DSM-IV codes, Brain, Research, PTSI, Mental, Movement, Pain, Organization, Disorder, Post-traumatic stress disorder, Patient, Acute stress disorder, National Council, Anesthesiology, Diagnostic and Statistical Manual of Mental Disorders, Trauma, Chronic pain, PTSD, Migraine, Meat

Therefore, Erase PTSD Now is petitioning for a name change and kicking off a national campaign for PTSD to now be referred to as PTSI.

Key Points: 
  • Therefore, Erase PTSD Now is petitioning for a name change and kicking off a national campaign for PTSD to now be referred to as PTSI.
  • "At Erase PTSD Now, our goal is to restore individuals, as well as affected families and communities, to a pre-trauma state.
  • We believe that changing the name from PTSD to PTSI is an important step in achieving that goal," explains Coleen LaCosta, Executive Director of Erase PTSD Now.
  • Erase PTSD Now is calling on individuals, organizations, and communities to join the movement and support efforts to change PTSD to PTSI: an Injury that is treatable.

Americans Express Worry Over Personal Safety in Annual Anxiety and Mental Health Poll

Retrieved on: 
Wednesday, May 10, 2023
American Psychiatric Association, Medicine, Violence, Anxiety, Parent, APA, Research, Climate change, Cannabis, Ketamine, Diagnosis, Morning Consult, Health, Mental health, Safety, Nursing, Gypsum, Health insurance

Each month, among other questions, the poll asks about levels of anxiety around current events.

Key Points: 
  • Each month, among other questions, the poll asks about levels of anxiety around current events.
  • About one-third (30%) of adults said they have talked with a mental health care professional about mental health issues before, a slight uptick from 2022 (+4).
  • The poll asked several questions about mental health treatments involving previously banned substances, such as cannabis, psychedelics, and ketamine.
  • Two-thirds (68%) of American adults say that children and teens have more mental health problems than they did a decade ago.